Two-period 21 Day Cross-over Study to Compare the Pharmacokinetics of Tiotropium From Two Inhalers

NCT03246581 | Completed Phase 1

• 1 other identifier: CSP-07-000040
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare the absorption of a test inhalation product with the reference product in healthy volunteers.

Conditions

Healthy

Keywords

inhalation; anticholinergic

Outcome Measures

Primary Outcomes (1)

• Peak Plasma Concentration (Cmax)

  noncompartmental analysis

  24 hours

Study Arms (2)

Test Product

EXPERIMENTAL

tiotropium pMDI 2 inhalations

Drug: Tiotropium

Commercial Product

ACTIVE COMPARATOR

tiotropium pMDI 2 inhalations

Drug: Tiotropium

Interventions

Tiotropium DRUG

inhalation

Also known as: Spiriva Respimat

Commercial Product; Test Product

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy Volunteer
• Willing and able to give informed consent
• Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic
• Subjects must agree to use an adequate method of contraception from admission through 12 weeks after last administration

You may not qualify if:

• Evidence or history of clinically significant abnormalities or disease or chronic respiratory disorders
• Any presence or history of a clinically significant allergy including any adverse reaction to study drug
• History of drug or alcohol abuse within the past 2 years
• Smoked tobacco within the past 6 months or have a history of more than 10- pack years (number of packs smoked per day x number of years smoked)
• Donation or loss of greater than 400 mL of blood within the previous 3 months
• Have received any prescription medication within 4 weeks or investigational medication within 12 weeks of study (exception: contraceptives are permitted)
• Have received any non-prescription medication within 14 days prior to dosing (exception: paracetamol use within 2 days)
• Upper respiratory tract infection (excluding otitis media) within 14 days of the first study day, or lower respiratory tract infection within the last 3 months
• If female, nursing, lactating or pregnant

Sponsors & Collaborators

• 3M: collaborator
• Kindeva Drug Delivery: lead
• Simbec Research: collaborator

Study Sites (1)

3M Health Care

Loughborough, United Kingdom

Location

MeSH Terms

Conditions

Respiratory Aspiration

Interventions

Tiotropium Bromide

Condition Hierarchy (Ancestors)

Respiration Disorders; Respiratory Tract Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Scopolamine Derivatives; Tropanes; Azabicyclo Compounds; Aza Compounds; Organic Chemicals; Alkaloids; Heterocyclic Compounds; Bridged Bicyclo Compounds, Heterocyclic; Heterocyclic Compounds, Bridged-Ring

Study Officials

• Victoria Sessions, PhD

  3M

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 9, 2017
• First Posted: August 11, 2017
• Study Start: July 13, 2017
• Primary Completion: January 21, 2018
• Study Completion: May 3, 2018
• Last Updated: December 4, 2025

Record last verified: 2024-11

Locations

GB (1)